Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7501432 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2 | |
| SCHEMBL10726476 | 0.79 | CTBP2 (0.39) | CYP11B1CYP11B2P2RX7IDO1SMN1; SMN2 | |
| SCHEMBL10726042 | 0.79 | CTBP2 (0.39) | CYP11B1CYP11B2P2RX7IDO1SMN1; SMN2 | |
| SCHEMBL10721467 | 0.77 | CYP11B1 (0.38) | RAB9AMEN1KMT2ACYP3A4CYP11B1 | |
| SCHEMBL10721473 | 0.77 | CYP11B1 (0.38) | RAB9AMEN1KMT2ACYP3A4CYP11B1 | |
| SCHEMBL3369458 | 0.76 | HTT (0.55) | RAB9ANPC1HPGDMAPK1IDO1 | |
| SCHEMBL10725110 | 0.73 | CYP11B1 (0.36) | RAB9ANPC1L3MBTL1MAPTMEN1 | |
| SCHEMBL10725109 | 0.73 | CYP11B1 (0.36) | RAB9ANPC1L3MBTL1MAPTMEN1 | |
| SCHEMBL20759409 | 0.73 | PREP (0.36) | CYP3A4CYP11B1CYP11B2IDO1LMNA | |
| SCHEMBL8916921 | 0.73 | PREP (0.36) | MEN1KMT2ACYP3A4MAPK1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | LES LABORATOIRES SERVIER (FR) | 2002-10-24 | — | — | US | disclosed |
| WO-2002057257-A1 | CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057258-A1 | CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| EP-1225170-A2 | Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier S.A. (FR) | 2002-07-24 | — | — | EP | disclosed |
| EP-0216424-A1 | Imidazoles, their preparation and their use as fungicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | COASY, FNTA, FNTB | RAB9A 755/4885NPC1 30/4885L3MBTL1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.